|N02CA72 - Ergotamine, Combinations with Psycholeptics||ATC-DDD Version 2016. Source: WHO|
|N02 - Analgesics|
This group comprises general analgesics and antipyretics.
All salicylic acid derivatives except combinations with corticosteroids (M01B) or opioids (N02AJ) are classified in N02BA - Salicylic acid and derivatives, as it is difficult to differentiate between the use of salicylates in rheumatic conditions and other therapeutic uses of salicylates.
All plain ibuprofen preparations are classified in M01A, even if they are only intended for use as pain relief.
There are a number of combined preparations, which contain analgesics and psycholeptics. These are classified in N02, as pain relief must be regarded as the main indication. Analgesics used for specific indications are classified in the respective ATC groups. E.g.:
A03EA- Antispasmodic/psycholeptics/analgesic combinations
M01 - Antiinflammatory and antirheumatic products
M02A - Topical products for joint and muscular pain
M03 - Muscle relaxants
See comments to these groups.
Lidocaine indicated for postherpetic pain is classified in N01BB.
|N02C - Antimigraine Preparations|
This group comprises preparations specifically used in the prophylaxis and treatment of migraine. Analgesics, see N02A and N02B.
Beta blocking agents, see C07.
Antivertigo preparations, see N07.
Cyproheptadine, see R06A - Antihistamines for systemic use.
Tolfenamic acid, see M01AG - Fenamates.
Indometacin in combination with prochlorperazine and caffeine is classified in M01AB51 - Indometacin, combinations.
Botulinum toxin used in the prophylactic treatment of migraine is classified in M03AX01.
|N02CA - Ergot Alkaloids|
Ergot alkaloids for gynecological use, see G02A and G02CB.
See also C04AE - Ergot alkaloids.
Dihydroergotamine, which is also used in the treatment of hypotension, is classified in this group.
Combinations of dihydroergotamine and etilefrine are classified in C01CA.
The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.
The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.
|N02CA72 - Ergotamine, Combinations with Psycholeptics|
|4 mg||O||Refers to ergotamine|